scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1018018880 |
P356 | DOI | 10.1186/1479-0556-6-10 |
P932 | PMC publication ID | 2276190 |
P698 | PubMed publication ID | 18334017 |
P5875 | ResearchGate publication ID | 5518271 |
P2093 | author name string | Yves Beuzard | |
Daniel Scherman | |||
Emmanuel Payen | |||
Emmanuelle E Fabre | |||
Pascal Bigey | |||
P2860 | cites work | Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats. | Q45876557 |
Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates | Q45879163 | ||
Hematology of a murine beta-thalassemia: a longitudinal study | Q45889556 | ||
Improvement of mouse beta-thalassemia by electrotransfer of erythropoietin cDNA. | Q57670350 | ||
A mouse model for β-thalassemia | Q70168656 | ||
Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy | Q70903398 | ||
Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: correlation of platelet count with erythropoietic activity and iron parameters | Q72390216 | ||
Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer | Q73595843 | ||
Inducible production of erythropoietin using intramuscular injection of block copolymer/DNA formulation | Q80828818 | ||
High-efficiency gene transfer into skeletal muscle mediated by electric pulses | Q35123357 | ||
Iron Deficiency and Erythropoiesis: New Diagnostic Approaches | Q35538677 | ||
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks | Q36096717 | ||
Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation | Q37210391 | ||
Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules | Q40413623 | ||
Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene | Q40961003 | ||
Comparison of various expression plasmids for the induction of immune response by DNA immunization. | Q41092520 | ||
Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators | Q42516387 | ||
Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts | Q42524485 | ||
Regulated expression of erythropoietin from an AAV vector safely improves the anemia of beta-thalassemia in a mouse model. | Q44426807 | ||
Human erythropoietin gene therapy for patients with chronic renal failure | Q45044565 | ||
pCOR: a new design of plasmid vectors for nonviral gene therapy | Q45861925 | ||
Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector | Q45866962 | ||
Autoimmune anemia in macaques following erythropoietin gene therapy | Q45871935 | ||
P921 | main subject | gene therapy | Q213901 |
P304 | page(s) | 10 | |
P577 | publication date | 2008-03-11 | |
P1433 | published in | Genetic Vaccines and Therapy | Q15767223 |
P1476 | title | Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment | |
P478 | volume | 6 |
Q37646523 | Emerging technologies in the delivery of erythropoietin for therapeutics |
Q36431079 | Long-term and stable correction of uremic anemia by intramuscular injection of plasmids containing hypoxia-regulated system of erythropoietin expression |
Q45864162 | Minimal doses of a sequence-optimized transgene mediate high-level and long-term EPO expression in vivo: challenging CpG-free gene design |
Q37924090 | New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials |
Search more.